Actavis and Forest Laboratories Receive FTC Second Request Under Hart-Scott-Rodino
Business Wire - Thu Apr 17, 3:05PM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that they have each received a request for additional information from the Federal Trade Commission ("FTC"
Forest Laboratories Has Returned 97.2% Since SmarTrend Recommendation (FRX)
Comtex SmarTrend(R) - Tue Apr 15, 9:34AM CDT
SmarTrend identified an Uptrend for Forest Laboratories (NYSE:FRX) on September 12th, 2013 at $44.30. In approximately 7 months, Forest Laboratories has returned 97.25% as of today's recent price of $87.37.
Legal Updates, Stock Price Movements, New Awareness Campaigns, and Senior-level Appointments - Analyst Notes on Mylan, WellPoint, Forest, Novatis and Intercept
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Mylan Inc. (NASDAQ: MYL), WellPoint Inc. (NYSE: WLP), Forest Laboratories Inc. (NYSE: FRX), Novatis AG (NYSE: NVS) and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1162-100free.
Global Depression Drugs Market 2014-2018 with GlaxoSmithKline plc, Eli Lilly & Co., Pfizer Inc., and Forest Laboratories Dominating
M2 - Mon Apr 14, 10:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gh6tqs/global_depression) has announced the addition of the "Global Depression Drugs Market 2014-2018 with GlaxoSmithKline plc, Eli Lilly & Co., Pfizer Inc., and Forest Laboratories Dominating" report to their offering. Increasing public awareness regarding depression and associated disorders is expected to increase the acceptability of various drugs, and thereby an increase in drug penetration. For instance, ADAP educates high school students, teachers, and parents about depression disorder. ADAP aims to increase awareness about mood disorders in young people while stressing the need for evaluation and treatment. Similarly, the Peer-to-Peer Depression Awareness Campaign project is the student education component of the educational collaboration between the Depression Center and Ann Arbor public schools. The project aims to educate high school students about depression and depressive illnesses, and support them in finding creative ways to deliver this knowledge to their peers in order to reduce stigma, raise awareness, and help to promote the early detection of depression, bipolar disorder, and related illnesses. According to the report, one of the main drivers in this market is the increase in the number of patients suffering from depression. The increasing aging population is contributing to the growth of the market. The number of patients suffering from depression is increasing owing to increasingly elevated stress levels, unhealthy lifestyle, and social imbalances both in developing and developed nations. Further, the report states that one of the main challenges is the generic erosion of key blockbuster drugs. The introduction of low-priced generic drugs increases competition among vendors and reduces the cost of patented/branded drugs substantially. Key vendors dominating this space are - GlaxoSmithKline plc - Eli Lilly & Co. - Pfizer Inc - Forest Laboratories Inc. Other vendors mentioned in the report are - Astra Zeneca plc - Bristol Myers Squibb Co - Mallinckrodt Pharmaceuticals Inc. - Sanofi Aventis S.A. - Takeda Pharmaceutical Company Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product Types - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Vendor Landscape - Key Vendor Analysis Visit http://www.researchandmarkets.com/research/gh...depression
Ironwood Pharmaceuticals and Forest Laboratories announce new LINZESS campaign
M2 - Fri Apr 11, 7:26AM CDT
US-based medicinal company Ironwood Pharmaceuticals (NasdaqGS:IRWD) and US-based Forest Laboratories (NYSE:FRX) launched on Thursday a new direct-to-consumer (DTC) patient awareness campaign for LINZESS (linaclotide) for treating adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
Favourable Rulings, Topline Results, Earnings Schedules, Approvals, and New Advisory Boards - Analyst Notes on Lilly, UnitedHealth Group, Valeant, Forest Laboratories, and Zoetis
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Eli Lilly & Co. (NYSE: LLY), UnitedHealth Group, Inc. (NYSE: UNH), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Forest Laboratories Inc. (NYSE: FRX), and Zoetis Inc. (NYSE: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
Regulatory Update from Forest Labs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 3:40PM CDT
Forest Labs and partner Almirall announced that the FDA has provided a feedback on their new drug application (NDA) for the fixed dose combination of Tudorza (aclidinium) and formoterol.
Biotech IPOs Adamas, Cerulean Slump In Trading Debut
at Investor's Business Daily - Thu Apr 10, 3:02PM CDT
Adamas Pharmaceuticals (ADMS) and Cerulean Pharma (CERU) launched IPOs Thursday, two of four biotechs expected to debut this week. Adamas priced at 16, the low end of its range. In late afternoon trading, the stock was near 15.30 on the stock market...
Adamas Pharma wavers after IPO raises $48 million
AP - Thu Apr 10, 10:40AM CDT
NEW YORK (AP) — Shares of Adamas Pharmaceuticals wavered Thursday after the drug developer's initial public offering raised $48 million.
Global Pain Management Therapeutics Market 2013-2019
M2 - Thu Apr 10, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dqrj96/pain_management) has announced the addition of the "Global Pain Management Therapeutics Market 2013-2019" report to their offering. Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline Global Pain Management Therapeutics Market 2013-2019 provides insights and analysis into the market. Pain is a widespread problem across the world. More than 25% of the total population suffers from some clinically significant pain in a year. Since pain considerably affects day-to-day activities in life, its management presents a considerable challenge for physicians. Inadequate pain control remains a major problem across the world. There is an urgent and unmet need to manage these pain-related problems accurately. Currently, the management of pain is not efficient due to low diagnosis and prescription rates. In many cases, such as cancer pain, 50% of the people taking medicines are not satisfied with the results. This is primarily due to the absence of a perfect pain management solution. Pain management can be most effective only when the underlying disease conditions are cured. However, there is no treatment that offers absolute relief for the indications covered in this report. The medications given for these indications are more for modifying the disease symptoms than offering complete relief from pain. The combination of under-managed pain, low awareness, and fear of addiction to some classes of pain medication is preventing people suffering pain from seeking treatment 100% of the time. Scope - Overview of the pain management market by analyzing the revenue, Annual Cost of Therapy (ACT) and treatment usage pattern across the top seven markets, which are the US, the UK, France, Germany, Spain, Italy and Japan. - Therapeutic landscape of the pain management therapeutics market and includes detailed market sizing and analysis of the trends in eight indications, which are fibromyalgia, neuropathic pain, cancer pain, Osteoarthritis (OA) pain, Rheumatoid Arthritis (RA) pain, migraine, Low Back Pain (LBP) and post-operative pain. - Geographical landscape of the pain management therapeutics market in the top seven markets, which are the US, the UK, France, Germany, Spain, Italy and Japan. - Detailed pipeline analysis of the pain management market (as of April 2013). The section also contains detailed analyses of the most promising pipeline molecules. - Profiles of the top companies operating in the pain management therapeutics market. - List of strategic consolidations, such as M&A deals, licensing agreements and partnership deals that took place in the global pain management therapeutics market between 2007 and 2013. Key Topics Covered: - Tables & Figures - Introduction - Market Overview - Therapeutic Landscape - Geographical Landscape - Asia-Pacific and China - Pipeline Analysis - Competitive Landscape - Strategic Consolidations - Management Therapeutics Market to 2019 - Appendix Companies Mentioned - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Johnson & Johnson - Pfizer Inc - Purdue Pharma - Teva Pharmaceuticals (Cephalon, Inc.) For more information visit http://www.researchandmarkets.com/research/dq...management
Ironwood and Forest Launch New Direct-to-Consumer Awareness Campaign For LINZESS(R)
Business Wire - Thu Apr 10, 7:30AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today that they have commenced a new direct-to-consumer (DTC) patient awareness campaign for LINZESS(R) (linaclotide), a once-daily treatment for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). The campaign aims to help adults suffering from IBS-C or CIC recognize the symptoms of these disorders, describe their symptoms to their doctor, and ask their doctor about LINZESS to help proactively manage their disease. The television portion of the campaign premiered last night on ABC.
Pipeline Progress at Prothena - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 11:00AM CDT
Prothena Corporation (PRTA) has initiated a randomized, double-blind, placebo-controlled phase I trial on its monoclonal antibody candidate, PRX002.
Health Care Sector Stocks under Review -- Research on Endo Intl., Dynavax Technologies, Forest Laboratories, and Orexigen Therapeutics
PR Newswire - Wed Apr 09, 9:14AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average advanced 0.06% to 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 4.04% in the last one month. Investor-Edge has initiated coverage on the following equities: Endo International PLC (NASDAQ: ENDP), Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX) and Orexigen Therapeutics Inc. (NASDAQ: OREX). Free technical research on ENDP, DVAX, FRX and OREX can be downloaded upon signing up at:
Forest Laboratories and Almirall Provide Update on the Fixed Dose Combination of Aclidinium and Formoterol in the U.S.
Business Wire - Wed Apr 09, 2:17AM CDT
Forest Laboratories, Inc. (NYSE:FRX) and Almirall, S.A. (ALM:MC) today announced that they have recently received feedback from the U.S. Food and Drug Administration (FDA) regarding the fixed dose combination of aclidinium and formoterol. Although no new issues have arisen, further discussion is needed with the Agency in order to address questions related to CMC (Chemistry, Manufacturing and Control) and a Type C meeting with the FDA is going to be requested, likely to be held during Q3 this year. Forest and Almirall believe that the fixed dose combination of aclidinium and formoterol can be an important therapy for U.S. COPD (Chronic Obstructive Pulmonary Disease) patients.
Forest Laboratories Falls 1.52% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Apr 08, 3:46PM CDT
Forest Laboratories (NYSE:FRX) traded in a range yesterday that spanned from a low of $85.30 to a high of $88.49. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $87.73 on volume of 7.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Forest Laboratories Set to Possibly Rebound After Yesterday's Selloff of 1.52%
Comtex SmarTrend(R) - Tue Apr 08, 3:46PM CDT
Forest Laboratories (NYSE:FRX) traded in a range yesterday that spanned from a low of $85.30 to a high of $88.49. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $87.73 on volume of 7.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Watch for Shares of Forest Laboratories (FRX) to Approach Support at $85.51
Comtex SmarTrend(R) - Tue Apr 08, 9:33AM CDT
Shares of Forest Laboratories (NYSE:FRX) have bearishly opened below the pivot of $89.28 today and have reached the first support level of $87.06. Investors may be interested in a cross of the next downside pivot targets of $85.51 and $81.74.